Linagliptin

• Type 2 Diabetes Mellitus
• Blood Sugar Control
• Diabetes with Kidney Disease
• DPP-4 Inhibitor Therapy

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. This oral medication improves glycemic control through the incretin pathway without requiring dose adjustment for renal impairment, making it a practical choice for patients with kidney disease.

Mechanism of Action

Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly degrades incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, linagliptin increases and prolongs the activity of these incretins. GLP-1 stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and promotes satiety. GIP also stimulates insulin secretion. The glucose-dependent nature of this mechanism means linagliptin has a low risk of causing hypoglycemia when used alone.

Available Formulations

Linagliptin is available as oral tablets containing 5 mg. It is also available in fixed-dose combinations with metformin (Jentadueto) and with empagliflozin (Glyxambi). The tablets can be taken with or without food.

Medical Uses

Linagliptin is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antidiabetic medications including metformin, sulfonylureas, pioglitazone, and insulin. Unlike most other DPP-4 inhibitors, linagliptin does not require dose adjustment in patients with renal impairment, making it particularly useful in this population.

Dosing Guidelines

The recommended dose is 5 mg once daily, taken at any time of day with or without food. No dose adjustment is required for renal impairment at any level, including end-stage renal disease requiring dialysis. No dose adjustment is required for hepatic impairment. When combined with insulin or insulin secretagogues (sulfonylureas), lower doses of these medications may be needed to reduce hypoglycemia risk.

Important Safety Information

Cases of acute pancreatitis, including fatal pancreatitis, have been reported. Patients should be instructed to discontinue linagliptin and contact their healthcare provider if persistent severe abdominal pain occurs. Severe and disabling arthralgia (joint pain) has been reported with DPP-4 inhibitors; consider as a possible cause of severe joint pain and discontinue if appropriate. Heart failure has been observed in some DPP-4 inhibitor trials; monitor for heart failure signs and symptoms. Bullous pemphigoid requiring hospitalization has been reported; discontinue if suspected.

Drug Interactions

Strong CYP3A4/P-gp inducers (rifampin) significantly reduce linagliptin exposure and may reduce efficacy; consider alternative glucose-lowering treatment. When combined with sulfonylureas or insulin, lower doses of these medications may be needed. Linagliptin does not significantly inhibit or induce CYP450 enzymes. No dose adjustment is needed with CYP3A4 or P-gp inhibitors.

Special Populations

There are no adequate studies in pregnant women; animal studies showed no harm. Use during pregnancy only if clearly needed. Linagliptin is excreted in rat milk; use caution during breastfeeding. Safety and efficacy have not been established in pediatric patients. Clinical trials included patients up to 80 years; no overall differences in safety or efficacy were observed in elderly patients. No dose adjustment is required for any degree of renal impairment, including ESRD on dialysis. No dose adjustment is required for hepatic impairment.